Tissue-derived mesenchymal stromal cells used as vehicles for anti-tumor therapy exert different in vivoeffects on migration capacity and tumor growth
Open Access
- 28 May 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 11 (1), 1-16
- https://doi.org/10.1186/1741-7015-11-139
Abstract
Background: Mesenchymal stem cells (MSCs) have been promoted as an attractive option to use as cellular delivery vehicles to carry anti-tumor agents, owing to their ability to home into tumor sites and secrete cytokines. Multiple isolated populations have been described as MSCs, but despite extensivein vitrocharacterization, little is known about theirin vivobehavior.The aim of this study was to investigate the efficacy and efficiency of different MSC lineages derived from five different sources (bone marrow, adipose tissue, epithelial endometrium, stroma endometrium, and amniotic membrane), in order to assess their adequacy for cell-based anti-tumor therapies. Our study shows the crucial importance of understanding the interaction between MSCs and tumor cells, and provides both information and a methodological approach, which could be used to develop safer and more accurate targeted therapeutic applications.Methods: We first measured thein vivomigration capacity and effect on tumor growth of the different MSCs using two imaging techniques: (i) single-photon emission computed tomography combined with computed tomography (SPECT-CT), using the human sodium iodine symporter gene (hNIS) and (ii) magnetic resonance imaging using superparamagnetic iron oxide. We then sought correlations between these parameters and expression of pluripotency-related or migration-related genes.Results: Our results show that migration of human bone marrow-derived MSCs was significantly reduced and slower than that obtained with the other MSCs assayed and also with human induced pluripotent stem cells (hiPSCs). The qPCR data clearly show that MSCs and hiPSCs exert a very different pluripotency pattern, which correlates with the differences observed in their engraftment capacity and with their effects on tumor growth.Conclusion: This study reveals differences in MSC recruitment/migration toward the tumor site and the corresponding effects on tumor growth. Three observations stand out: 1) tracking of the stem cell is essential to check the safety and efficacy of cell therapies; 2) the MSC lineage to be used in the cell therapy needs to be carefully chosen to balance efficacy and safety for a particular tumor type; and 3) different pluripotency and mobility patterns can be linked to the engraftment capacity of the MSCs, and should be checked as part of the clinical characterization of the lineage.Keywords
This publication has 65 references indexed in Scilit:
- Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through METNature Medicine, 2012
- MMP-2 mediates mesenchymal stem cell tropism towards medulloblastoma tumorsGene Therapy, 2011
- Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth?The International Journal of Cell Cloning, 2010
- Stem cells as vectors for antitumour therapyThorax, 2010
- Effects of transplantation of adipose tissue‐derived stem cells on prostate tumorThe Prostate, 2010
- Human Bone Marrow–Derived Mesenchymal Stem Cells for Intravascular Delivery of Oncolytic Adenovirus Δ24-RGD to Human GliomasCancer Research, 2009
- Isolation and Culture of Epithelial Progenitors and Mesenchymal Stem Cells from Human Endometrium1Biology of Reproduction, 2009
- Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcomaThe Journal of Experimental Medicine, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based TherapiesTissue Engineering, 2001